Incyte (INCY) was upgraded by
Weiss Ratings from "hold (c+)" to "buy (b-)".
Incyte Corporation (INCY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Lilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata [Yahoo! Finance]
Does Incyte's 2025 Beat And 2026 Guidance Shift The Bull Case For INCY? [Yahoo! Finance]
Incyte Corp. (INCY) Reports Q4 2025 Revenue Growth of 28% to $1.51B Driven by Jakafi and Opzelura Sales [Yahoo! Finance]